| Target Price | ¥2,958.00 |
| Price | ¥3,161.00 |
| Deviation |
6.42%
register free of charge
|
| Number of Estimates | 6 |
|
6 Analysts have issued a price target MediPal 2027 .
The average MediPal target price is ¥2,958.00.
This is
6.42%
register free of charge
¥3,234.00
2.31%
register free of charge
¥2,686.60
15.01%
register free of charge
|
|
| A rating was issued by 11 analysts: 0 Analysts recommend MediPal to buy, 6 to hold and 5 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the MediPal stock has an average upside potential 2027 of
6.42%
register free of charge
|
| Mar '26 |
2027 Estimates |
|
|---|---|---|
| Revenue Billion ¥ | 3,817.35 | 3,967.18 |
| 3.98% | 3.92% | |
| EBITDA Margin | 1.75% | 1.84% |
| 7.11% | 5.21% | |
| Net Margin | 1.11% | 1.05% |
| 1.56% | 5.76% |
6 Analysts have issued a sales forecast MediPal 2027 . The average MediPal sales estimate is
This results in the following potential growth metrics:
6 Analysts have issued an MediPal EBITDA forecast 2027. The average MediPal EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
6 MediPal Analysts have issued a net profit forecast 2027. The average MediPal net profit estimate is
This results in the following potential growth metrics and future Net Margins:
| Mar '26 |
2027 Estimates |
|
|---|---|---|
| Earnings Per Share ¥ | 206.67 | 204.06 |
| 6.98% | 1.26% | |
| P/E | 15.49 | |
| EV/Sales | 0.07 |
6 Analysts have issued a MediPal forecast for earnings per share. The average MediPal EPS is
This results in the following potential growth metrics and future valuations:
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


